GlassScriptPhysician profile
Keesag A Baron
NPI 1891736930
$14,974.94
in general payments reported to CMS, 2019-2025
36 companies · $27.42 in 2025
The $27.42 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,794 · 2020: $1,945 · 2021: $2,362 · 2022: $2,243 · 2023: $1,870 · 2024: $1,733 · 2025: $27.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,621 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,621.45 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,962.27 | 2019-2024 | |
| Boston Scientific Corporation | $1,862.29 | 2019-2023 | Watchman Flx, Ams 800 Artificial Urinary Sphincter, Ekosonic |
| Amgen INC. | $1,470.29 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $1,110.34 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,105.14 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $940.85 | 2019-2024 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $853.32 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.79 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $586.48 | 2019-2024 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $507.05 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $472.40 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $452.40 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $441.45 | 2021-2025 | Verquvo |
| Biotronik INC. | $403.87 | 2019-2021 | |
| Medtronic, INC. | $381.33 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $351.26 | 2019-2023 | Aveir |
| Philips North America LLC | $230.84 | 2019-2024 | (Ck4) Mcot |
| Medtronic Vascular, INC. | $191.42 | 2019-2020 | |
| Abiomed | $155.02 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $138.64 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $105.55 | 2019-2020 | |
| Sensible Medical Innovations INC | $79.90 | 2024 | Reds System |
| Chiesi USA, INC. | $50.44 | 2019 | |
| Janssen Scientific Affairs, LLC | $47.99 | 2019 | |
| Esperion Therapeutics, INC. | $38.97 | 2020-2021 | |
| Daiichi Sankyo INC. | $35.84 | 2021 | |
| Gilead Sciences, INC. | $34.72 | 2019 | |
| Amryt Pharma Holdings LTD | $32.87 | 2020-2021 | |
| Bardy Diagnostics, INC. | $30.90 | 2022 | |
| Irhythm Technologies, INC. | $29.45 | 2020 | |
| Janssen Biotech, INC. | $24.05 | 2021 | |
| Shockwave Medical, INC | $22.84 | 2022 | |
| Heartflow, INC. | $19.32 | 2022 | |
| Bard Peripheral Vascular, INC. | $18.57 | 2019 | |
| Teleflex LLC | $16.77 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keesag Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.